Bing

SEARCH HISTORY

Trade-Ideas LLC identified Zogenix ( ZGNX) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Zogenix as such a stock due to the following factors: ZGNX has an average dollar-volume (as ...
The Street · 5/29/2015
Equities research analysts at Brean Capital set a $2.50 price objective on shares of Zogenix (NASDAQ:ZGNX) stock in a research note issued to investors on Thursday. The firm currently has a a “buy” rating on the stock. Brean Capital’s price objective ...
Mideast Times · 5/28/2015
Shares of Zogenix (NASDAQ:ZGNX) have earned an average recommendation of “Buy” from the seven brokerages that are covering the stock, StockRatingsNetwork.com reports. One analyst has rated the stock with a hold rating and five have assigned a …
Ticker Report · 5/29/2015
More from Bing News
... focus on updating investors with recent news on the U.S. stock market about the small and penny stocks, issues news alert on Zogenix, Inc.(NASDAQ:ZGNX), Galena Biopharma, Inc. (NASDAQ:GALE), Retrophin, Inc. (NASDAQ:RTRX). Zogenix, Inc.
Market News Call · 5/27/2015
Zogenix, Inc. (ZGNX)’S monthly performance stands at – 9.740% and Zogenix, Inc. (ZGNX) is considered a stock to watch today has an analyst rating of 1.50 iBio, Inc. (IBIO) of the Healthcare sector has gained 4.
wallstreetscope.com · 5/27/2015
Unlike Zohydro from ZNGX, Purdue Pharma’s drug is more difficult to crush — making it harder for addicts to abuse the drug. Both drugs are powerful painkillers designed to treat chronic lower back pain. The potential for Zohydro abuse prompted the FDA ...
Investor Place · ByChristopher Freeburn · 3/12/2014
Zogenix Inc. (ZGNX) experienced unusually high volume on May. 29, as the stock gained 14.09% to a closing price of $1.70. The stock saw 9.04 million shares trade hands over the course of the day on 15,850 trades. Given that the stock’s average daily ...
Equities · 5/29/2015
About Zogenix Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with CNS disorders who need …
Financial Content · 5/27/2015
Dravet syndrome
Zogenix (NASDAQ:ZGNX)‘s stock had its “outperform” rating reissued by research analysts at Oppenheimer in a report released on Tuesday. They currently have a $2.50 price objective on the stock. Oppenheimer’s price objective indicates a potential ...
sleekmoney.com · 5/13/2015
Zogenix, Inc. (ZGNX) was a big mover last session, as the company shares rose over 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the …
Yahoo Finance · 10/6/2014